The supplier of raw materials for the beauty industry has just announced the acquisition of several actives developed by the American biotechnology company Amyris. Givaudan owns Neossance® Squalane (a high-performance emollient), Neossance® Hemisqualane (an alternative to plant-based silicones) and CleanScreen™ (a long-lasting sunscreen), among others.
Givaudan and Amyris have signed a long-term partnership agreement under which Amyris will continue to manufacture ingredients that Givaudan will use in cosmetics, and will provide access to its innovation capabilities. Givaudan will become the marketing partner for these future ingredients.
“I am delighted with this transaction which fits perfectly with our 2025 strategic ambitions to grow our active beauty business while leveraging our leadership in biotechnology in partnership with Amyris’ expertise. Going forward, we will continue to push the boundaries of biotechnology, imagining sustainable innovations for a better future of beauty,” said Maurizio Volpi, President of Givaudan Fragrance & Beauty.
The terms of the agreement include a combination of immediate cash consideration and an earn-out, as well as a long-term manufacturing agreement.
The planned transaction remains subject to formal approvals by the relevant regulatory authorities and is expected to close in the first half of 2023.
